BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet Trial

Reuters

9 hours ago

Feb 23 (Reuters) - MacroGenics Inc MGNX.O:

MACROGENICS ANNOUNCES PAUSING OF ENROLLMENT OF NEW STUDY PARTICIPANTS IN LINNET TRIAL
MACROGENICS INC: U. S. FOOD AND DRUG ADMINISTRATION (FDA) HAS PLACED A PARTIAL CLINICAL HOLD ON ITS PHASE 2 LINNET STUDY OF LORIGERLIMAB
MACROGENICS INC: CURRENT STUDY PARTICIPANTS MAY CONTINUE TO RECEIVE STUDY DRUG
MACROGENICS: FDA'S PARTIAL CLINICAL HOLD INITIATED AFTER CO'S NOTIFICATION TO FDA OF TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIAL
MACROGENICS: TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIAL DUE TO OCCURRENCE OF RECENT SAFETY EVENTS

Source text: ID:nGNX7pFkgg

Further company coverage: MGNX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613755071"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613755071\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613755071?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 07:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613755071","market":"nz","top_or_hot":-1,"title":"BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet Trial</title></head><body><p><span>Feb 23 (Reuters)</span><span> - </span>MacroGenics Inc <span>MGNX.O</span>:</p><ul><li><p>MACROGENICS ANNOUNCES PAUSING OF ENROLLMENT OF NEW STUDY PARTICIPANTS IN LINNET TRIAL</p></li><li><p>MACROGENICS INC:  U. S. FOOD AND DRUG ADMINISTRATION (FDA) HAS PLACED A PARTIAL CLINICAL HOLD ON ITS PHASE 2 LINNET STUDY OF LORIGERLIMAB</p></li><li><p>MACROGENICS INC: CURRENT STUDY PARTICIPANTS MAY CONTINUE TO RECEIVE STUDY DRUG</p></li><li><p>MACROGENICS: FDA'S PARTIAL CLINICAL HOLD INITIATED AFTER CO'S NOTIFICATION TO FDA OF TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIAL</p></li><li><p>MACROGENICS: TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIAL DUE TO OCCURRENCE OF RECENT SAFETY EVENTS</p></li></ul><p>Source text: <span>ID:nGNX7pFkgg</span></p><p>Further company coverage: <span>MGNX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 07:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet Trial</title></head><body><p><span>Feb 23 (Reuters)</span><span> - </span>MacroGenics Inc <span>MGNX.O</span>:</p><ul><li><p>MACROGENICS ANNOUNCES PAUSING OF ENROLLMENT OF NEW STUDY PARTICIPANTS IN LINNET TRIAL</p></li><li><p>MACROGENICS INC:  U. S. FOOD AND DRUG ADMINISTRATION (FDA) HAS PLACED A PARTIAL CLINICAL HOLD ON ITS PHASE 2 LINNET STUDY OF LORIGERLIMAB</p></li><li><p>MACROGENICS INC: CURRENT STUDY PARTICIPANTS MAY CONTINUE TO RECEIVE STUDY DRUG</p></li><li><p>MACROGENICS: FDA'S PARTIAL CLINICAL HOLD INITIATED AFTER CO'S NOTIFICATION TO FDA OF TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIAL</p></li><li><p>MACROGENICS: TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIAL DUE TO OCCURRENCE OF RECENT SAFETY EVENTS</p></li></ul><p>Source text: <span>ID:nGNX7pFkgg</span></p><p>Further company coverage: <span>MGNX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nFWN3ZJ1BR:1","article_id":"2613755071","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613755071","pubTimestamp":1771889475,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet TrialFeb 23 (Reuters) - MacroGenics Inc MGNX.O:MACROGENICS ANNOUNCES PAUSING OF ENROLLMENT OF NEW STUDY PARTICIPAN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MGNX":"MacroGenics Inc."},"translate_title":"简介-Macrogenics宣布暂停Linnet试验新研究参与者的招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGNX":0.9},"content_text":"BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet TrialFeb 23 (Reuters) - MacroGenics Inc MGNX.O:MACROGENICS ANNOUNCES PAUSING OF ENROLLMENT OF NEW STUDY PARTICIPANTS IN LINNET TRIALMACROGENICS INC:  U. S. FOOD AND DRUG ADMINISTRATION (FDA) HAS PLACED A PARTIAL CLINICAL HOLD ON ITS PHASE 2 LINNET STUDY OF LORIGERLIMABMACROGENICS INC: CURRENT STUDY PARTICIPANTS MAY CONTINUE TO RECEIVE STUDY DRUGMACROGENICS: FDA'S PARTIAL CLINICAL HOLD INITIATED AFTER CO'S NOTIFICATION TO FDA OF TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIALMACROGENICS: TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIAL DUE TO OCCURRENCE OF RECENT SAFETY EVENTSSource text: ID:nGNX7pFkggFurther company coverage: MGNX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}